Archive: 08/09/2017
New data confirms superiority of docetaxel based triplet therapy in gastric cancer
The superiority of docetaxel based triplet therapy over standard care in patients with resectable oesophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress ...
Sep 8, 2017
Patients with high risk prostate cancer may benefit 'equally' from two new treatments
Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid. (1)
Sep 8, 2017
LORELEI: Taselisib boosts breast tumor shrinkage
Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor positive and HER2-negative (ER+/HER2-) according to results of the LORELEI ...
Sep 8, 2017
Rucaparib boosts progression-free survival in BRCA mutant recurrent ovarian cancer
Rucaparib maintenance therapy increases progression-free survival in BRCA mutant recurrent ovarian cancer by 77%, according to late-breaking results from the ARIEL3 trial reported today at the ESMO 2017 Congress in Madrid.
Sep 8, 2017
Under-reporting of vertebral fractures by radiologists: A missed opportunity
Vertebral fractures are the most common osteoporotic fractures. People with osteoporotic vertebral fragility fractures (VFFs) are at increased risk of future fractures, including potentially devastating and life-threatening ...
Sep 8, 2017